UNSPSC 85355303: Diagnosis of elastosis perforans serpiginosa

This classification denotes the group of activities that yields a diagnosis of Elastosis perforans serpiginosa. Elastosis perforans serpiginosa is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as a four digit category under code L87. 2

UNSPSC 85355303 Diagnosis of elastosis perforans serpiginosa is a Commodity code that does not map to the recent state and local procurement activity tagged under it. The three opportunities posted between January and July 2026 involve diagnostic imaging systems (PACS), ultrasound equipment, and phlebotomy services — none of which relate to the diagnosis or treatment of elastosis perforans serpiginosa, a rare connective-tissue disorder. The code appears to be a medical-classification tag incorrectly applied to procurement notices, creating a significant disconnect between the taxonomy label and actual buying activity.

The recent opportunities do reflect legitimate state and local health care procurement: San Mateo County Medical Center posted an RFP for enterprise-grade Picture Archiving and Communication System (PACS) implementation with proposals due August 7, 2026; Collier County, Florida issued a notice of intent to single-source ultrasound equipment (KOSMOS platform with TORSO-ONE probe and five-year warranty) from EchoNous, Inc.; and the Albuquerque Police Department posted an RFB for 24/7 on-call phlebotomy services covering Bernalillo County with a three-year initial term renewable to five years total. These solicitations span California, Florida, and New Mexico and involve county health systems and municipal police departments. However, because the code's nominal scope (diagnosis of a specific dermatologic condition) bears no relationship to what is actually being bought under this code designation, the code does not serve as a reliable identifier for procurement opportunity in this category. Firms should verify code accuracy with the issuing jurisdiction before investing in pursuit strategy.